Custom immune checkpoint monoclonal antibody discovery focuses on developing highly specific antibodies that target immune regulatory pathways. These monoclonal antibodies are designed to modulate immune responses, particularly in cancer immunotherapy and autoimmune disease treatment. Researchers employ advanced techniques such as hybridoma technology, phage display, and B cell sorting to optimize antibody specificity and efficacy.